Enhanced Serum Proteolysis Resistance of cell-penetrating Peptides

References

• Vlieghe P Lisowski V Martinez J Khrestchatisky M . Synthetic therapeutic peptides: science and market. Drug Discov. Today15 (1-2), 40–56 (2010).
   PubMed Web of Science ®Google Scholar
• Gautam A Singh H Tyagi A et al. CPPsite: a curated database of cell penetrating peptides. Database (Oxford) doi:10.1093/database/bas015 (2012).
   PubMed Web of Science ®Google Scholar
• Gao X Kim KS Liu D . Nonviral gene delivery: what we know and what is next. AAPS J.9 (1), E92–E104 (2007).
   PubMed Web of Science ®Google Scholar
• Walther W Stein U Shoemaker RH Schlag PM . Chemotherapy-inducible vector for gene therapy of cancer. Methods Mol. Med.35, 371–392 (2000).
   PubMedGoogle Scholar
• Milletti F . Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today17 (15–16), 850–860 (2012).
   PubMed Web of Science ®Google Scholar
• Koren E Torchilin VP . Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med.18 (7), 385–393 (2012).
   PubMed Web of Science ®Google Scholar
• Myrberg H Zhang L Mae M Langel U . Design of a tumor-homing cell-penetrating peptide. Bioconjug. Chem.19 (1), 70–75 (2008).
   PubMed Web of Science ®Google Scholar
• Olson ES Jiang T Aguilera TA et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. USA107 (9), 4311–4316 (2010).
   PubMed Web of Science ®Google Scholar
• Bitler BG Schroeder JA . Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat. Anticancer Drug Discov.5 (2), 99–108 (2010).
   PubMed Web of Science ®Google Scholar
• Heitz F Morris MC Divita G . Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol.157 (2), 195–206 (2009).
   PubMed Web of Science ®Google Scholar
• Nestor JJ Jr . The medicinal chemistry of peptides. Curr. Med. Chem.16 (33), 4399–4418 (2009).
   PubMed Web of Science ®Google Scholar
• Adkins JN Varnum SM Auberry KJ et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell Proteomics1 (12), 947–955 (2002).
   PubMed Web of Science ®Google Scholar
• Vlieghe P Khrestchatisky M . Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system. Ther. Deliv.1 (4), 489–494 (2010).
   PubMedGoogle Scholar
• Witt KA Gillespie TJ Huber JD Egleton RD Davis TP . Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides22 (12), 2329–2343 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar D Bhalla TC . Microbial proteases in peptide synthesis: approaches and applications. App. Microbio. Biotechnol.68 (6), 726–736 (2005).
   PubMed Web of Science ®Google Scholar
• Reyal F Guyader C Decraene C et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res.14 (1), R11 (2012).
   PubMed Web of Science ®Google Scholar
• Cottu P Marangoni E Assayag F et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res. Treat.133 (2), 595–606 (2012).
   PubMed Web of Science ®Google Scholar
• Arrouss I Nemati F Roncal F et al. Specific targeting of Caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS ONE8 (4), e60816 (2013).
   PubMed Web of Science ®Google Scholar
• Marangoni E Vincent-Salomon A Auger N et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res.13 (13), 3989–3998 (2007).
   PubMed Web of Science ®Google Scholar
• Vasconcelos L Parn K Langel U . Therapeutic potential of cell-penetrating peptides. Ther. Deliv.4 (5), 573–591 (2013).
   PubMedGoogle Scholar
• Warso MA Richards JM Mehta D et al. A first-in-class, first-in-human, Phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer.108 (5), 1061–1070 (2013).
   PubMed Web of Science ®Google Scholar
• Guergnon J Dessauge F Dominguez V et al. Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol. Pharmacol.69 (4), 1115–1124 (2006).
   PubMed Web of Science ®Google Scholar
• Palm C Jayamanne M Kjellander M Hallbrink M . Peptide degradation is a critical determinant for cell-penetrating peptide uptake. Biochim. Biophys. Acta1768 (7), 1769–1776 (2007).
   PubMed Web of Science ®Google Scholar
• Trehin R Merkle HP . Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm.58 (2), 209–223 (2004).
   PubMed Web of Science ®Google Scholar
• Elmquist A Hansen M Langel U . Structure–activity relationship study of the cell-penetrating peptide pVEC. Biochim. Biophys. Acta1758 (6), 721–729 (2006).
   PubMed Web of Science ®Google Scholar
• Sun TL Sun Y Lee CC Huang HW . Membrane permeability of hydrocarbon-cross-linked peptides. Biophys. J.104 (9), 1923–1932 (2013).
   PubMed Web of Science ®Google Scholar
• Montrose K Yang Y Sun X Wiles S Krissansen GW . Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Sci. Rep.3, 1–7 (2013).
   Web of Science ®Google Scholar
• Rink R Arkema-Meter A Baudoin I et al. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods61 (2), 210–218 (2010).
   PubMed Web of Science ®Google Scholar
• Holm T Andaloussi SE Langel U . Comparison of CPP uptake methods. Methods Mol. Biol.683, 207–217 (2011).
   PubMedGoogle Scholar
• Sarko D Beijer B Garcia Boy R et al. The pharmacokinetics of cell-penetrating peptides. Mol. Pharm.7 (6), 2224–2231 (2010).
   PubMedGoogle Scholar
• Jia L Gorman GS Coward LU et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol.68 (2), 513–524 (2011).
   PubMed Web of Science ®Google Scholar